Table 2.
Clinical trials of CAR-T cells
| Target | Identifier | Institution | Phase | Status | Disease | Comments |
|---|---|---|---|---|---|---|
| EGFR | NCT02331693 | Shanghai Cancer Institute | I | Recruiting | Glioma | Autologous T cells transduced with a lentiviral vector |
| EGFRvIII | NCT02844062 | Beijing Sanbo Brain Hospital | I | Recruiting | Glioma | Lymphodepletion chemotherapy, followed by CAR-T |
| EGFRvIII | NCT01454596 | National Cancer Institute (NCI) | I/II | Recruiting | Glioma | Autologous T cells, a retroviral vector |
| EGFRvIII | NCT02209376 | University of Pennsylvania/University of California | I | Recruiting | Glioma | Autologous T cells, a lentiviral vector |
| EGFRvIII | NCT02664363 | Duke University Medical Center | I | Not yet recruiting | Glioma | Dose escalation cohorts for 4 dose levels |
| EGFR | NCT01869166 | Chinese PLA General Hospital | I/II | Completed | NSCLC | Safe and feasible |
| HER2 | NCT02713984 | Southwest Hospital, China | I/II | Recruiting | HER2-positive cancer | |
| HER2 | NCT01935843 | Chinese PLA General Hospital | I/II | Recruiting | HER2-positive cancer | |
| HER2 | NCT02547961 | Fuda Cancer Hospital Guangzhou | I/II | Recruiting | Breast cancer | A retrovirus vector, preconditioning treatment |
| HER2 | NCT02442297 | Baylor College of Medicine | I | Recruiting | Glioma | Intracranial injection |
| HER2 | NCT01109095 | Baylor College of Medicine | I | Active, not recruiting | Glioma | CMV-specific cytotoxic T cells (CMV-T cells) |
| HER2 | NCT00889954 | Baylor College of Medicine | I | Active, not recruiting | HER2-positive cancer | TGFBeta resistant HER2/EBV-CTLs |
| HER2 | NCT00924287 | National Cancer Institute (NCI) | I/II | Completed | HER2-positive sarcoma | Results is not encouraging |
| HER2 | NCT00902044 | Baylor College of Medicine | I/II | Completed | HER2-positive sarcoma | Safe and feasible |
| MSLN | NCT02930993 | China Meitan General Hospital | I | Recruiting | Mesothelin-positive tumors | Followed lymphodepletion |
| MSLN | NCT02706782 | Shanghai Renji Hospital | I | Recruiting | Pancreatic cancer | Transcatheter arterial infusion |
| MSLN | NCT02159716 | University of Pennsylvania | I | Active not recruiting | Mesothelin-positive tumors | Lentiviral transduced |
| MSLN | NCT02792114 | Memorial Sloan Kettering Cancer Center | I | Recruiting | Mesothelin-expressing breast cancer | Premedicated with acetaminophen and diphenhydramine, and administered cyclophosphamide |
| MSLN | NCT02465983 | University of Pennsylvania | I | Active not recruiting | Pancreatic cancer | Combination therapy with CART-meso cells and CART19 cells |
| MSLN | NCT02959151 | Shanghai Tumor Hospital | I/II | Recruiting | Pancreatic cancer | Combined with interventional therapy |
| MSLN | NCT02590747 | Chinese PLA General Hospital | I | Recruiting | Mesothelin-positive tumors | Retroviral vector-transduced |
| MSLN | NCT01355965 | University of Pennsylvania | I | Completed | Pleural mesothelioma | Safe and feasible |
| MSLN | NCT02414269 | Memorial Sloan Kettering Cancer Center | I | Recruiting | Malignant pleural disease | With/without chemotherapy |
| MSLN | NCT01583686 | National Cancer Institute (NCI) | I/II | Recruiting | Mesothelin-positive tumors | Followed lymphodepletion |
| MSLN | NCT01897415 | University of Pennsylvania | I | Active not recruiting | Pancreatic ductal adenocarcinoma (PDA) | Transfected with chimeric anti-mesothelin immunoreceptor SS1 |
| IL13Rα2 | NCT00730613 | City of Hope Medical Center | I | Completed | Glioblastoma | Safe and feasible |
| IL13Rα2 | NCT02208362 | City of Hope Medical Center | I | Completed | Glioblastoma | Safe and feasible |
| CEA | NCT01373047 | Roger Williams Medical Center | I | Completed | Liver metastases | Safe and feasible |
| FAP | NCT01722149 | University of Zurich | I | Recruiting | Malignant pleural mesothelioma | Followed lymphodepletion |
| GD2 | NCT00085930 | Baylor College of Medicine | I | Completed | Neuroblastoma | Safe and feasible |
| GD2 | NCT02107963 | National Cancer Institute (NCI) | I | Completed | Sarcoma Osteosarcoma Neuroblastoma Melanoma |
Safe and feasible |
| CD133 | NCT02541370 | Chinese PLA General Hospital | I | Recruiting | CD133-positive malignancies | Relapsed and/or chemotherapy refractory advanced malignancies |
The details of Table 2 derived from http://clinicaltrials.gov/